LOGIN

ABOUT US

We are transforming genetic testing

Genetic disorders are caused by a wide variety of DNA changes that, until now, have required different technologies to detect. Traditional methodologies biochemically extract a slice of the DNA and then sequence it. This approach has produced a vast number of different tests that are designed to detect specific DNA changes within certain limitations.  Identifying the right test for the patient is often challenging. Further complicated by limited sensitivity and specificity, this leads to missed or delayed diagnoses and increased residual risk.

Our whole genome sequence (WGS) based methodology is shifting the genetic testing paradigm, overcoming the limitations of traditional technologies. We sequence the entire DNA and then slice the data in any number of relevant ways for analysis. With its ability to detect all major types of genetic variation, our Genomic Unity® testing methodology provides a better test at a lower overall cost to patients and payors.

Our interdisciplinary team of talented medical professionals, bioinformaticians, software engineers, information technology and operations professionals are leading the way to better genetic testing, one patient at a time

OUR TEAM

Haim Neerman

CEO

Noam Shomron, PhD

CSO

Yaron Rachmany

COO

Christine Stanley PhD, FACMG

Chief Director Clinical Genomics

Tomer Jackman

VP Customer Support and Lab Services

Chris Zerwas

VP Sales

Daryl Spinner, PhD

VP Market Access and Reimbursement

Stephanie Zichi, MBA

Senior Product Manager

BOARD OF DIRECTORS

Guy Ezekiel, MD

Chairman

Hillel Bachrach

Board Member

Greg Faust, PhD

Board Member

Haim Neerman

Board Member

Zafrira Avnur, Ph.D.

Board Member

INVESTORS

Licenses

CLIA # 22D2140582    |     CAP # 8291875     |    MA State License # 5438     

CA State License # CDS00800949    |    MD State License # 2894     |    PA State License # 36456     |    RI State License # LCO01241

NPI# 1629512140

Haim Neerman
CEO

Haim’s career spans over 20 years of technology entrepreneurship. Prior to co-founding Variantyx, Haim co-founded Credorax Inc. – a global credit card acquiring bank, Fabrix systems (acquired by Ericson), Bandwiz Inc. and Actil Ltd.

Haim is a physics, math and computer science graduate of the Talpiot program / Hebrew University of Jerusalem.

Linkedin-in

Noam Shomron, PhD
CSO

Professor Noam Shomron heads the Genomic Intelligence Research Laboratory at the Faculty of Medicine at Tel Aviv University. Professor Shomron leads a multidisciplinary team of scientists consisting of biologists, physicians, engineers, bioinformaticians and mathematicians. His team aims to deepen our understanding of disease etiology in order to generate a significant impact through translating ideas into clinical reality.

Professor Shomron is also the Director of the Djerassi Institute of Oncology; Director of Rare Genomics Israel a non-profit organization that assists children and families with undiagnosed genetic disorders; Academic Director of ScienceAbroad; Editor of “Deep Sequencing Data Analysis” Springer Production book, Edition I/II and co-founder of several Biotech companies.

Linkedin-in

Yaron Rachmany
COO

Yaron Rachmany oversees Variantyx’ IT systems and business processes. Prior to joining Variantyx, Yaron served as Director of Systems Operations and as a Director of IT Applications at Semtech Corporation (NASDAQ: SMTC). Prior to Semtech Yaron held the VP of Information Systems position with Credorax. Prior to Credorax, Yaron held senior Information Systems positions with Microsemi (NASDAQ: MSCC), Intel (NASDAQ: INTC) and ECI Telecom.

Yaron holds an M.Sc. and a B.Sc. in Industrial Engineering and Management (specialized in Information Systems) from Ben Gurion University in Israel.

Linkedin-in

Christine Stanley PhD, FACMG
Chief Director Clinical Genomics

As Variantyx’s Chief Director of Clinical Genomics, Christine is responsible for overseeing clinical genomic interpretations and regulatory compliance for the clinical laboratory. Prior to joining Variantyx, Christine held positions as Head of Clinical Laboratory at WuXi NextCODE, Chief Director of Clinical Genomics at Courtagen Life Sciences and Genetics Director at Athena Diagnostics. She maintains a part-time appointment as Clinical Laboratory Director of QnA Diagnostics.

Christine holds a Bachelor’s degree in Genetics from Texas A&M University and a PhD in Human Genetics from the Medical College of Virginia with fellowship training at Boston University in clinical molecular genetics. She is a diplomate of the American Board of Medical Genetics and Genomics and a Fellow of the American College of Medical Genetics and Genomics.

Linkedin-in

Tomer Jackman
VP Customer Support and Lab Services

As VP Customer Support and Lab Services, Tomer is responsible for delivering services to customers. Prior to co-founding Variantyx, Tomer was responsible for hardware development operations in the Pivotal/Greenplum division of EMC2 where he helped develop server clusters for “Massive Parallel Processing” databases. This followed a decade with EMC2 in several hardware engineering roles and work in R&D with HP/Indigo.

Tomer holds a high-tech MBA from Northeastern University in Boston, and a BSc in Electrical Engineering from Tel-Aviv University.

Linkedin-in

Christopher Zerwas
VP Sales

Chris serves as the VP of Sales. Chris’ primary focus is to drive revenue growth by leading a sales team to educate clinicians, and their supporting staff, about Variantyx’s genomic testing capabilities and services.  Chris brings 20 years of clinical genetic testing experience to Variantyx. Prior to Variantyx, Chris held senior sales management positions with Perkin Elmer Genomics, GeneDx and Athena Diagnostics.

Chris holds a Bachelor’s degree in Marketing from Pacific University.

Linkedin-in

Daryl Spinner, PhD
VP Market Access and Reimbursement

As Variantyx’s Vice President of Market Access and Reimbursement, Daryl is responsible for working with payors to expand patient access to clinically relevant genetic testing. Prior to joining Variantyx, Daryl held positions as Managing Director of Strategy at Evidera and Senior Director of Managed Care and Reimbursement at Courtagen Life Sciences.

Daryl holds a Bachelor’s degree in Chemistry and a PhD in Molecular and Cellular Pharmacology from the State University of New York at Stony Brook and an MBA from Duke University.

Linkedin-in

Guy Ezekiel, MD
Chairman

Guy joined the Pitango HealthTech team in May 2018 after serving as a Venture Partner at the fund for two years. In addition to Variantyx, he currently serves on the Board of Directors of Alike and Keepmed. Guy formerly served as the President and CEO of Ventor Technologies, a Pitango portfolio company and developer of revolutionary trans-catheter valves for the Cardiology market. In 2009 Ventor was acquired by Medtronic (NYSE: MDT). Following the acquisition, Guy was appointed General-Manager/Vice President at Medtronic. During his career, Guy served as the President & CEO of Brainsway (TLV: BRIN), President & CEO of Marval Pharma, and Senior Executive at the Pittsburgh headquarters of Medrad, Inc., a wholly owned subsidiary of Bayer Healthcare (FWB: BAYN).

Guy holds an MD from Ben-Gurion University of the Negev and an MBA (cum laude) from the University of Pittsburgh.

Linkedin-in

Hillel Bachrach
Board Member

Hillel is the Managing Partner of 20/20 HealthCare Partners, LLC, (20/20 HCP), a global investment entity he founded in 2005. 20/20 HCP has invested in many successful companies including Viztek (acquired by Konica Minolta in 2015), Corindus Vascular Robotics (purchased by Siemens HealthCare in 2019), XR Health, SQZ Biotechnology, Verseau Therapeutics and EnClear Therapies. In addition to Varianytx, Hillel currently serves on the Board of Directors for Zixi and Velocamp. Hillel previously served as president of Odin Medical Technologies, Inc., and helped found UltraSPECT, Ltd., the leader in providing sophisticated dose and procedure time reduction software solutions for nuclear medicine procedures which was sold to Pharmalogic in 2019.

Hillel received a BS in electrical engineering from Technion Israeli Institute of Technology and an MBA from the Kellogg Graduate School of Management.

Linkedin-in

Greg Faust, PhD
Board Member

Greg has managed many software product development projects, usually from the ground up. He held executive positions at Microsoft and two successful software start-up companies, one of which went public, and another acquired. In 2015, he completed an interdisciplinary PhD in genomics. His research focused on the development of novel genomic analysis algorithms, especially for the identification of structural variants in WGS data. He then joined Variantyx as CTO, and was instrumental in architecting the analysis pipeline used in the Genomic Unity® products. Having served on three previous boards, Greg continues as a member of the Board of Directors and angel investor in Variantyx. He also maintains his public domain open-source bioinformatics tools used in labs around the world.


Greg holds a BS in Computer Science from the University of Michigan, a MS in Computer Science from the Massachusetts Institute of Technology, and a PhD in Biochemistry and Molecular Genetics from the Medical School of the University of Virginia.

Linkedin-in

Zafrira Avnur, Ph.D.
Board Member

Chief Scientific officer and partner at Quark Venture Inc.

Prior to Quark, Dr. Avnur was the Global Head of Academic Innovation, Roche Partnering 2009 – 2016. She was responsible for creating relationships with the world’s leading academic institutions and world class innovators, gaining Roche early access to innovation.  She has created eleven startup companies.

Dr. Avnur was named Global Head of Neglected Diseases Roche Partnering 2010-2012.

Preceding her academic innovation leadership role, Dr. Avnur assumed responsibility for scientific evaluations of partnering opportunities and started the “Finder” group for Biomarkers for all therapeutic areas at Roche. She acted as Liaison between Pharma and Diagnostic Divisions and contributed to the PHC (Personalized Health Care) initiative.

Prior to her partnering roles, Dr. Avnur worked in pharmaceuticals and diagnostics research and development for nearly 20 years. She held number positions progressing from scientist and manager to global responsibilities. In this role, she was overseeing the advancement of compounds from the bench into the clinic, and was involved in the design and execution of early clinical studies that characterize the pharmacodynamics and clinical effects of a number of compounds.

 In her management roles, Dr. Avnur ran groups of up to 44 scientists.

Dr. Avnur was named Distinguished Scientist, the highest scientific appointment at Roche.

Major scientific achievements include advancing three compounds (a PTHrP analog and two vitamin D analogs, for the treatment of postmenopausal osteoporosis) from early exploratory discovery research to the clinic.

 

Linkedin-in

Please do not submit Protected Health Information (PHI) through this email address.

If you need to submit Protected Health Information (PHI), please call us at 617-209-2090 and we will work with you to submit the information through an alternate mechanism.

Otherwise, please continue: